Myriad: Q2 Earnings Snapshot

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $116.1 million in its second quarter.

The Salt Lake City-based company said it had a loss of $1.42 per share. Losses, adjusted for non-recurring costs and stock option expense, came to 8 cents per share.

The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share.

The molecular diagnostic company posted revenue of $183.5 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $186 million.

Myriad expects full-year results to range from a loss of 36 cents per share to a loss of 24 cents per share, with revenue in the range of $730 million to $750 million.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on MYGN at

Copyright © 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.

Federal News Network Logo

More from WTOP

Log in to your WTOP account for notifications and alerts customized for you.

Sign up